

**Motion passed by the NCMS Executive Board**  
**– October 24, 2019**

**The NCIMS Executive Board supports the recommendation by FDA that the current drug residue testing pilot protocol of testing for individual drugs, initiated by Proposal #15-211, be discontinued by the Appendix N Modification Committee and that the Committee explore a new approach in partnership with the NCIMS and FDA – to strengthen our system to minimize the risk of drug residues in milk, including means of verification to ensure the system is being effectively implemented.**